Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥3,930 JPY
Change Today -105.00 / -2.60%
Volume 1.7M
4507 On Other Exchanges
Symbol
Exchange
Munich
Tokyo
OTC US
OTC US
As of 1:45 AM 05/7/15 All times are local (Market data is delayed by at least 15 minutes).

shionogi & co ltd (4507) Snapshot

Open
¥3,930
Previous Close
¥4,035
Day High
¥4,015
Day Low
¥3,910
52 Week High
04/9/15 - ¥4,440
52 Week Low
05/7/14 - ¥1,738
Market Cap
1.4T
Average Volume 10 Days
1.7M
EPS TTM
¥92.41
Shares Outstanding
351.1M
EX-Date
03/27/15
P/E TM
42.5x
Dividend
¥52.00
Dividend Yield
1.33%
Current Stock Chart for SHIONOGI & CO LTD (4507)

Related News

No related news articles were found.

shionogi & co ltd (4507) Related Businessweek News

No Related Businessweek News Found

shionogi & co ltd (4507) Details

Shionogi & Co., Ltd. manufactures and distributes pharmaceuticals, diagnostic reagents, medical devices, etc. primarily in Asia, North America, and Europe. Its principal products include various prescription drugs, including Osphena to treat postmenopausal vulvar and vaginal atrophy; Crestor tablets for the treatment of hyperlipidemia; Irbetan tablets for the treatment of hypertension; Cymbalta capsules to treat depression, depressive condition, and diabetic neuropathic pain; cancer pain analgesics, such as OxyContin tablets, OxiNorm powders, and OxiFast injections; Tivicay tablets for HIV treatment; Finibax and Finibax solution kit for intravenous drip infusion; Differin gel for the treatment of topical acne vulgaris; Pirespa tablets used to treat idiopathic pulmonary fibrosis; and Rapiacta, an antiviral drug for the treatment of influenza. The company also offers over the counter drugs comprising Popon series of multiple vitamin supplements; and Sedes, a line of analgesic antipyretics. In addition, it provides diagnostics reagents, such as Shionospot Reader and Shionospot BNP, a human brain natriuretic peptide kit; Allerport TARC, a thymus and activation-regulated chemokine kit; Allerport HRT, a reagent for identifying allergens; Brightpoc Flu, an influenza virus diagnostic kit; and Checkart Reader for measuring hemoglobin A1c and glucose levels in blood for use in diagnosing diabetes and other related clinical conditions. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

6,165 Employees
Last Reported Date: 06/25/14
Founded in 1878

shionogi & co ltd (4507) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

shionogi & co ltd (4507) Key Developments

Shionogi & Co., Ltd Receives Approval of STG320 from the Japanese Health Authorities

STALLERGENES S.A. announced that its partner, Shionogi & Co., Ltd. has received the approval of STG320 from the Japanese health authorities (PMDA - Pharmaceuticals and Medical Devices Agency). STG320 is the first immunotherapy tablet registered in Japan for the treatment of house dust mite induced allergic rhinitis. Since September 2010, Shionogi & Co., Ltd. has been the exclusive partner of STALLERGENES for the clinical development, registration, marketing and sales of sublingual house dust mite immunotherapy tablets and sublingual Japanese cedar pollen immunotherapy tablets. The approval of STG320 triggers the payment by Shionogi & Co., Ltd. of €10 million to STALLERGENES. STALLERGENES will also receive compensation on sales of STG320 in Japan. Allergic rhinitis affects 25% of Japan’s population and asthma 6.7%. House dust mites and Japanese cedar pollen are the two main causes of respiratory allergies in this country. STG320 has been the subject of a phase II /III clinical study in Japan (S-524101). This randomized, double-blind and placebo-controlled study has evaluated the efficacy and safety of a 12 month course of treatment with sublingual house dust mites immunotherapy tablets. On 3 February 2014, Shionogi reported that the study achieved its primary efficacy endpoint, as the treated groups have demonstrated a statistically significant difference on the Average Adjusted Symptom Score over one year of treatment versus the placebo group. Overall, the safety and tolerability profile were favourable.

Shionogi & Co., Ltd. Provides Update on Naldemedine

Shionogi & Co., Ltd. announced that Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by the company met its primary and secondary endpoints in a phase III study (COMPOSE I) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain receiving opioid therapy. Study results showed that naldemedine (0.2 mg tablet given once daily) statistically significantly improved the frequency of spontaneous bowel movement (SBM) compared with placebo over 12 weeks. Naldemedine was generally well-tolerated with the most commonly reported side effects being gastrointestinal disorders. This is the first phase III data generated from the COMPOSE program. COMPOSE I is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The study was designed to evaluate the efficacy and safety of naldemedine therapy, versus placebo, in 547 patients receiving chronic opioid therapy, who experience OIC accompanied by chronic non-cancer pain.

Shionogi & Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2015; Announces Consolidated Financial Results for the Nine Months Ended December 31, 2014; Provides Earnings Guidance for the Year Ending March 31, 2015

Shionogi & Co., Ltd. provided a dividend guidance of ¥24.0 per share for the year ending March 31, 2015, compared to ¥24.0 paid for the same period a year ago. The company announced consolidated financial results for the nine months ended December 31, 2014. For the period, the company reported net sales of ¥200,269 million against ¥218,099 million a year ago. Operating income was ¥36,066 million against ¥48,787 million a year ago. Ordinary income was ¥51,722 million against ¥49,976 million a year ago. Income before income taxes and minority interests was ¥56,226 million against ¥54,283 million a year ago. Net income was ¥26,261 million or ¥78.56 per diluted share against ¥36,160 million or ¥107.98 per diluted share a year ago. For the year ending March 31, 2015, the company now expects net sales of ¥273,500 million, operating income of ¥49,500 million, ordinary income of ¥58,000 million and net income of ¥30,000 million or ¥90.33 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4507:JP ¥3,930.00 JPY -105.00

4507 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.54 USD -0.31
Pfizer Inc $33.46 USD -0.66
Theravance Inc $15.56 USD -1.04
View Industry Companies
 

Industry Analysis

4507

Industry Average

Valuation 4507 Industry Range
Price/Earnings 43.7x
Price/Sales 4.9x
Price/Book 2.8x
Price/Cash Flow 45.9x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIONOGI & CO LTD, please visit www.shionogi.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.